abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation

Author

World J Gastrointest Pathophysiol. 2020 Aug 12;11(5):104-113.doi: 10.4291/wjgp.v11.i5.104.

Simcha Weissman 1, Preetika Sinh 2, Tej I Mehta 3, Rishi K Thaker 4, Abraham Derman 5, Caleb Heiberger 3, Nabeel Qureshi 1, Viralkumar Amrutiya 1, Adam Atoot 1, Maneesh Dave 6, James H Tabibian 7

Author Information

1 Department of Medicine, Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ 07047, United States.

2 Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, United States. psinh@mcw.edu.

3 Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57108, United States.

4 Department of Medicine, New York Presbyterian, Brooklyn, NY 11215, United States.

5 Department of Medicine, Mount Sinai-Saint Luke's Roosevelt, NY 10025, United States.

6 Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, CA 95817, United States.

7 Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, United States.

Abstract

Inflammatory bowel disease (IBD) causes systemic vascular inflammation. The increased risk of venous as well as arterial thromboembolic phenomena in IBD is well established. More recently, a relationship between IBD and atherosclerotic cardiovascular disease (ASCVD) has been postulated. Systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have well characterized cardiac pathologies and treatments that focus on prevention of disease associated ASCVD. The impact of chronic inflammation on ASCVD in IBD remains poorly characterized. This manuscript aims to review and summarize the current literature pertaining to IBD and ASCVD with respect to its pathophysiology and impact of medications in order to encourage further research that can improve understanding and help develop clinical recommendations for prevention and management of ASCVD in patients with IBD.